Sangamo will design and engineer ZFNs that target genes supplied by Genentech.
Sangamo BioSciences entered into a second research and license agreement with Genentech to include additional targets for potential improvement of production cell lines using Sangamo’s zinc finger DNA-binding protein nuclease (ZFN) technology.
“Under this second nonexclusive, research and commercial license agreement, Sangamo will design and engineer additional ZFNs that target genes identified by Genentech to potentially improve protein pharmaceutical production in mammalian cells,” explains Edward Lanphier, Sangamo’s president and CEO.
